Search
Bicara Therapeutics Inc
BCAXAdd to Watchlist
24.560USD
+1.330+5.73%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
1.39BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
15
analysts
Buy
Current Rating
31.462
Target Price
+35.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Bicara Therapeutics Inc
BCAX
15
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
How have Bicara Therapeutics IncBCAX's recent earnings per share performed?
The market expectation was USD -0.93, while Bicara Therapeutics IncBCAX's earnings per share (EPS) for the previous quarter was USD -0.68. EPS for the next quarter is expected at USD -0.83.
What is the analyst rating for Bicara Therapeutics Inc?
Based on the ratings of Bicara Therapeutics Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
